Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
Retrieved on:
Monday, December 18, 2023
Health, Other Consumer, Consumer, Women, Other Health, Pharmaceutical, Biotechnology, Galcanezumab, Sale, Norton Lilly International, Vomiting, Woman, Migraine, NYSE, Headache, Disease, Patient, Light, OGN, Eli Lilly and Company, Nausea, Disability, Central nervous system, CGRP, Education, Pharmaceutical industry, Lilly, Organon
RAYVOW is a first-in-class serotonin 5-HT1F receptor agonist approved for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
Key Points:
- RAYVOW is a first-in-class serotonin 5-HT1F receptor agonist approved for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
- “This commercialization agreement aligns seamlessly with Organon’s suite of central nervous system treatments in our Established Brands portfolio and, most importantly, it further bolsters our offerings to women, who are disproportionately impacted by migraine,” said Kevin Ali, Organon CEO.
- “We are confident this collaboration with Organon will help even more people throughout Europe gain access to our innovative migraine treatments.”
Under the terms of the agreement, Organon will become the sole distributor and promoter of Emgality and RAYVOW in Europe. - Total consideration to be paid to Lilly includes an upfront payment of $50 million and sales-based milestone payments.